Xiaojie Lu

List of Publications by Citations

Source: https://exaly.com/author-pdf/3159375/xiaojie-lu-publications-by-citations.pdf

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

63
papers1,617
citations21
h-index38
g-index72
ext. papers2,138
ext. citations6.5
avg, IF5.28
L-index

#	Paper	IF	Citations
63	T Cell Dysfunction in Cancer Immunity and Immunotherapy. <i>Frontiers in Immunology</i> , 2019 , 10, 1719	8.4	121
62	CRISPR-Cas9: a new and promising player in gene therapy. <i>Journal of Medical Genetics</i> , 2015 , 52, 289-96	5.8	115
61	Decreased levels of serum exosomal miR-638 predict poor prognosis in hepatocellular carcinoma. Journal of Cellular Biochemistry, 2018 , 119, 4711-4716	4.7	95
60	Competing endogenous RNA interplay in cancer: mechanism, methodology, and perspectives. <i>Tumor Biology</i> , 2015 , 36, 479-88	2.9	94
59	CRISPR-Cas9 for in vivo Gene Therapy: Promise and Hurdles. <i>Molecular Therapy - Nucleic Acids</i> , 2016 , 5, e349	10.7	92
58	Pseudogene in cancer: real functions and promising signature. <i>Journal of Medical Genetics</i> , 2015 , 52, 17-24	5.8	75
57	Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities. <i>Oncotarget</i> , 2017 , 8, 90521-90531	3.3	62
56	14-3-3 delivered by hepatocellular carcinoma-derived exosomes impaired anti-tumor function of tumor-infiltrating T dymphocytes. <i>Cell Death and Disease</i> , 2018 , 9, 159	9.8	59
55	Immunotherapy for hepatocellular carcinoma: recent advances and future perspectives. <i>Therapeutic Advances in Medical Oncology</i> , 2019 , 11, 1758835919862692	5.4	54
54	LINE-1 in cancer: multifaceted functions and potential clinical implications. <i>Genetics in Medicine</i> , 2016 , 18, 431-9	8.1	47
53	Oridonin, a novel lysine acetyltransferases inhibitor, inhibits proliferation and induces apoptosis in gastric cancer cells through p53- and caspase-3-mediated mechanisms. <i>Oncotarget</i> , 2016 , 7, 22623-31	3.3	45
52	The long noncoding RNA NEAT1 contributes to hepatocellular carcinoma development by sponging miR-485 and enhancing the expression of the STAT3. <i>Journal of Cellular Physiology</i> , 2018 , 233, 6733-674	₁ 7	43
51	NEAT1 upregulates TGF-II to induce hepatocellular carcinoma progression by sponging hsa-mir-139-5p. <i>Journal of Cellular Physiology</i> , 2018 , 233, 8578-8587	7	43
50	Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives. <i>Biomarker Research</i> , 2020 , 8, 35	8	41
49	CRISPR-Cas9 for medical genetic screens: applications and future perspectives. <i>Journal of Medical Genetics</i> , 2016 , 53, 91-7	5.8	30
48	Exosomes derived from exhausted CD8+ T cells impaired the anticancer function of normal CD8+ T cells. <i>Journal of Medical Genetics</i> , 2019 , 56, 29-31	5.8	29
47	Krppel-like factors in hepatocellular carcinoma. <i>Tumor Biology</i> , 2015 , 36, 533-41	2.9	28

(2021-2014)

46	CE-MS based on moving reaction boundary method for urinary metabolomic analysis of gastric cancer patients. <i>Electrophoresis</i> , 2014 , 35, 1032-9	3.6	28
45	Applications and advances of CRISPR-Cas9 in cancer immunotherapy. <i>Journal of Medical Genetics</i> , 2019 , 56, 4-9	5.8	27
44	New Insights into the Epithelial-to-Mesenchymal Transition in Cancer. <i>Trends in Pharmacological Sciences</i> , 2016 , 37, 246-248	13.2	25
43	Therapeutics for advanced hepatocellular carcinoma: Recent advances, current dilemma, and future directions. <i>Journal of Cellular Physiology</i> , 2019 , 234, 12122-12132	7	25
42	T cell exhaustion in cancer: Mechanisms and clinical implications. <i>Journal of Cellular Biochemistry</i> , 2018 , 119, 4279-4286	4.7	20
41	Delivery of a chemotherapeutic drug using novel hollow carbon spheres for esophageal cancer treatment. <i>International Journal of Nanomedicine</i> , 2017 , 12, 6759-6769	7-3	20
40	Gut microbiome and cancer immunotherapy. <i>Journal of Cellular Physiology</i> , 2020 , 235, 4082-4088	7	20
39	Therapeutic advances for patients with intermediate hepatocellular carcinoma. <i>Journal of Cellular Physiology</i> , 2019 , 234, 12116-12121	7	20
38	Genetic and phenotypic difference in CD8 T cell exhaustion between chronic hepatitis B infection and hepatocellular carcinoma. <i>Journal of Medical Genetics</i> , 2019 , 56, 18-21	5.8	20
37	Krppel-like factor 2 promotes liver steatosis through upregulation of CD36. <i>Journal of Lipid Research</i> , 2014 , 55, 32-40	6.3	19
36	Microwave ablation of hepatocellular carcinoma as first-line treatment: long term outcomes and prognostic factors in 221 patients. <i>Scientific Reports</i> , 2016 , 6, 32728	4.9	19
35	Comprehensive treatments for hepatocellular carcinoma with portal vein tumor thrombosis. <i>Journal of Cellular Physiology</i> , 2019 , 234, 1062-1070	7	18
34	DDX11-AS1 as potential therapy targets for human hepatocellular carcinoma. <i>Oncotarget</i> , 2017 , 8, 441	9 5,4 42	02 7
33	Four differentially methylated gene pairs to predict the prognosis for early stage hepatocellular carcinoma patients. <i>Journal of Cellular Physiology</i> , 2018 , 233, 6583-6590	7	16
32	Safety and efficacy of TACE and gamma knife on hepatocellular carcinoma with portal vein invasion. <i>Gut</i> , 2016 , 65, 715-6	19.2	15
31	Cancer immunotherapy: challenges and clinical applications. <i>Journal of Medical Genetics</i> , 2019 , 56, 1-3	5.8	15
30	Identification of TAF1, HNF4A, and CALM2 as potential therapeutic target genes for liver fibrosis. Journal of Cellular Physiology, 2019 , 234, 9045-9051	7	15
29	Functional tissue-engineered bone-like graft made of a fibrin scaffold and TG2 gene-modified EMSCs for bone defect repair. <i>NPG Asia Materials</i> , 2021 , 13,	10.3	14

28	Assessment of liver fibrosis with the gamma-glutamyl transpeptidase to platelet ratio: a multicentre validation in patients with HBV infection. <i>Gut</i> , 2018 , 67, 1903-1904	19.2	14
27	Hsa_circ_0070963 inhibits liver fibrosis via regulation of miR-223-3p and LEMD3. <i>Aging</i> , 2020 , 12, 1643-	1 6 . 5 5	13
26	Krppel-like factor 2 promotes cell proliferation in hepatocellular carcinoma through up-regulation of c-myc. <i>Cancer Biology and Therapy</i> , 2016 , 17, 20-6	4.6	12
25	Identification of copy number variation-driven genes for liver cancer via bioinformatics analysis. Oncology Reports, 2014 , 32, 1845-52	3.5	11
24	Towards In Silico Prediction of the Immune-Checkpoint Blockade Response. <i>Trends in Pharmacological Sciences</i> , 2017 , 38, 1041-1051	13.2	10
23	The pros and cons of dying tumour cells in adaptive immune responses. <i>Nature Reviews Immunology</i> , 2017 , 17, 591	36.5	10
22	Tolerability and efficacy of gamma knife radiosurgery on hepatocellular carcinoma with portal vein tumor thrombosis. <i>Oncotarget</i> , 2016 , 7, 3614-22	3.3	10
21	PPAR Antagonizes Hypoxia-Induced Activation of Hepatic Stellate Cell through Cross Mediating PI3K/AKT and cGMP/PKG Signaling. <i>PPAR Research</i> , 2018 , 2018, 6970407	4.3	10
20	Management of patients with intermediate stage hepatocellular carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920970840	5.4	9
19	The LGMN pseudogene promotes tumor progression by acting as a miR-495-3p sponge in glioblastoma. <i>Cancer Letters</i> , 2020 , 490, 111-123	9.9	9
18	Identification of LINC01615 as potential metastasis-related long noncoding RNA in hepatocellular carcinoma. <i>Journal of Cellular Physiology</i> , 2019 , 234, 12964-12970	7	9
17	Lack of Aquaporin 9 Reduces Brain Angiogenesis and Exaggerates Neuronal Loss in the Hippocampus Following Intracranial Hemorrhage in Mice. <i>Journal of Molecular Neuroscience</i> , 2017 , 61, 351-358	3.3	7
16	Laparoscopic Microwave Ablation of Hepatocellular Carcinoma at Liver Surface: Technique Effectiveness and Long-Term Outcomes. <i>Technology in Cancer Research and Treatment</i> , 2019 , 18, 15330	3 ² 37818	8 ⁷ 24338
15	Modeling cancer processes with CRISPR-Cas9. <i>Trends in Biotechnology</i> , 2015 , 33, 317-9	15.1	7
14	The landscape of DNA methylation in hepatocellular carcinoma. <i>Journal of Cellular Physiology</i> , 2019 , 234, 2631-2638	7	7
13	Study on the relationship between insulin growth factor 1 and liver fibrosis in patients with chronic hepatitis C with type 2 diabetes mellitus. <i>Journal of Cellular Biochemistry</i> , 2018 , 119, 9513-9518	4.7	5
12	DACH1 inhibits glioma invasion and tumor growth via the Wnt/catenin pathway. <i>OncoTargets and Therapy</i> , 2018 , 11, 5853-5863	4.4	5
11	FibroBox: a novel noninvasive tool for predicting significant liver fibrosis and cirrhosis in HBV infected patients. <i>Biomarker Research</i> , 2020 , 8, 48	8	4

LIST OF PUBLICATIONS

10	Circular RNA Circ0021205 Promotes Cholangiocarcinoma Progression Through MiR-204-5p/RAB22A Axis. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 653207	5.7	4
9	Managerial Decision-making for Daily Case Allocation Scheduling and the Impact on Perioperative Quality Assurance. <i>Translational Perioperative and Pain Medicine</i> , 2016 , 1, 20-30	1.7	3
8	Discovery of a novel, potent and selective small-molecule inhibitor of PD-1/PD-L1 interaction with robust in vivo anti-tumour efficacy. <i>British Journal of Pharmacology</i> , 2021 , 178, 2651-2670	8.6	3
7	Anticancer Opportunity Created by Loss of Tumor Suppressor Genes. <i>Technology in Cancer Research and Treatment</i> , 2016 , 15, 729-731	2.7	2
6	Pseudogene transcripts: Participants in tumorigenicity and promising therapeutic targets. <i>Leukemia Research</i> , 2016 , 42, 105-6	2.7	1
5	Metabolomic profiling of neoplastic lesions in mice. <i>Methods in Enzymology</i> , 2014 , 543, 261-73	1.7	1
4	CRISPR screen: a high-throughput approach for cancer genetic research. <i>Clinical Genetics</i> , 2015 , 88, 32-3	34	1
3	Pseudogene: promising signature for cancer reclassification: comment on "The Pan-Cancer analysis of pseudogene expression reveals biologically and clinically relevant tumour subtypes", Nat Commun. 2014; 5:3963. <i>Medical Oncology</i> , 2015 , 32, 354	3.7	1
2	Placental Immune Tolerance and Organ Transplantation: Underlying Interconnections and Clinical Implications. <i>Frontiers in Immunology</i> , 2021 , 12, 705950	8.4	O
1	Pitfalls in the non-invasive assessment of liver fibrosis with eLIFT-FM algorithm. <i>Journal of Hepatology</i> , 2018 , 68, 602-603	13.4	